Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nordion Inc Announces Update On Europe-Focused Phase III Clinical Trial For TheraSphere Yttrium-90 Liver Cancer Treatment


Thursday, 6 Sep 2012 08:00am EDT 

Nordion Inc announced that it has provided an update on its YES-P clinical trial for TheraSphere, the Company’s Yttrium-90 (Y-90) glass microsphere liver cancer treatment, by naming the principal investigators (PI) and contract research organization (CRO) for the study. The trial will be conducted in collaboration with Theorem Clinical Research, a global full-service CRO, which is also conducting Nordion’s two other Phase III clinical trials – EPOCH and STOP-HCC. YES-P is a randomized, multi-centre Phase III clinical trial to evaluate the safety and efficacy of TheraSphere vs. sorafenib in the treatment of patients with portal vein thrombosis (PVT) associated with unresectable hepatocellular carcinoma (HCC), the common form of primary liver cancer. 

Company Quote

12.95
0.01 +0.08%
23 Jul 2014